P1.03-26 Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis

Recently, Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in non-small-cell lung cancer. While the genetic spectrum of DDR2 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring DDR2 mutations. A total of 283 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of DDR2 mutation and other genes were detected by next generation sequencing. DDR2 gene mutation rate was 3.18% (9/283) in non-small cell lung cancer, including S311N (3 patients), E44K (1 patient), R709Q (1 patient), T564I (1 patient), R742Q (1 patient), G206* (1 patient) and M117I (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, all patients were DDR2 gene with co-occurring mutation. Briefly, patients with (n=6) or without (n=3) co-occurring EGFR mutations had a median OS of 20.0 months and 9.0 months respectively (P=0.29); patients with (n=4) or without (n=5) co-occurring TP53 mutations had a median OS of 17.0 months and 21.5 months respectively (P=0.63); patients with (n=2) or without (n=7) co-occurring KRAS mutations had a median OS of 13.5 months and 20.0 months respectively (P=0.82); patients with (n=2) or without (n=7) co-occurring PTPRD mutations had a median OS of 15.0 months and 20.0 months respectively (P=0.96). DDR2 mutations were observed in 3.18 % of cases of NSCLC. DDR2-mutated NSCLC can exhibit other driver gene alterations. No clinical characteristics were significantly associated with DDR2 mutation.